Bio-Path Holdings, Inc. BPTH shares are falling on Friday.
The company reported fourth-quarter earnings per share of $4.23 loss, narrower than the estimate of $5.40 loss.
Bio-Path reported a net loss of $33.63 per share for the year ended Dec. 31, 2023, lower than $38.12 per share in the year-ago period.
Research and development expense for the full year increased to $11.6 million, compared to $9.2 million in the year-ago period.
As of Dec. 31, 2023, the company had cash of $1.1 million, compared to $10.4 million as of Dec. 31, 2022.
In December, Bio-Path announced the completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002, evaluating the ability of BP1002 for the treatment of refractory/relapsed lymphoma and refractory/relapsed CLL patients.
“As we look to the months and year ahead, we expect to build on the clinical progress achieved to date to bring potentially life-saving new medicines to patients battling cancers,” Bio-Path CEO Peter Nielsen said.
Price Action: BPTH shares are trading lower by 4.98% to $5.920 on the last check Friday.
Read Next: Taiwan Semiconductor Manufacturing Stock Is Up Over 5% – What’s Going On?
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.